BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
Priority Review
TEPEZZA (teprotumumab) by Amgen is insulin-like growth factor-1 receptor inhibitors [moa]. First approved in 2020.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPEZZA (teprotumumab) is a monoclonal antibody that inhibits the insulin-like growth factor-1 receptor (IGF-1R), blocking a key pathway in thyroid eye disease pathogenesis. It is administered as an intravenous injection and represents the first and only FDA-approved treatment for thyroid eye disease (TED), a rare autoimmune condition affecting the tissues around the eye.
$0.129BPart D
PeakGrowing
TEPEZZA is at peak lifecycle with strong commercial momentum; teams are focused on maximizing market penetration in TED specialty care channels and expanding awareness among ophthalmologists and endocrinologists.
Mechanism of Action
Insulin-like Growth Factor-1 Receptor Inhibitors
Pharmacologic Class:
Insulin-like Growth Factor-1 Receptor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
Started Dec 2025
92 enrolled
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
Started Nov 2025
50 enrolled
Thyroid Eye Disease
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
Started Aug 2025
20 enrolled
Healthy Volunteers
Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
Started Jul 2025
5 enrolled
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
Started Jul 2024
89 enrolled
Thyroid Eye Disease
Worked on TEPEZZA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.